<DOC>
	<DOC>NCT00092170</DOC>
	<brief_summary>The purpose of this study is to determine the effect of an approved medication for adults for an investigational use in pediatric patients 3 months to 17 years for the treatment of complicated intra-abdominal infections or acute pelvic infections.</brief_summary>
	<brief_title>An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)</brief_title>
	<detailed_description>The duration of treatment is 18 months.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Pelvic Infection</mesh_term>
	<mesh_term>Pelvic Inflammatory Disease</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<mesh_term>Ticarcillin</mesh_term>
	<criteria>Patients aged 3 months to 17 years with intraabdominal infection or acute pelvic infection Immune problems Kidney problems</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Intra-abdominal infections</keyword>
	<keyword>Acute pelvic infections</keyword>
</DOC>